GRI Bio, Inc. Files 8-K with Regulatory Updates
Ticker: GRI · Form: 8-K · Filed: Aug 20, 2025 · CIK: 1824293
Sentiment: neutral
Topics: 8-K, regulatory-filing, financials
TL;DR
GRI Bio filed an 8-K on 8/20/25 for Reg FD and financials. Nothing major, just standard updates.
AI Summary
GRI Bio, Inc. filed an 8-K on August 20, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates routine corporate reporting, including financial updates and disclosures, which are important for investors to stay informed about the company's status.
Risk Assessment
Risk Level: low — This filing appears to be a routine corporate disclosure and does not indicate any immediate significant risks or events.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing with the SEC)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- GRI Bio, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- August 20, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific information is being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in this header information.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the content of these documents is not detailed in the provided header.
When did GRI Bio, Inc. change its name from Vallon Pharmaceuticals, Inc.?
The filing indicates the former company name was Vallon Pharmaceuticals, Inc. and the date of name change was 20200910.
What is the business address of GRI Bio, Inc.?
The business address is 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the fiscal year end for GRI Bio, Inc.?
The fiscal year end for GRI Bio, Inc. is December 31st (1231).
Filing Stats: 455 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-08-20 09:28:49
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20250820.htm (8-K) — 23KB
- gri_investorpresentation.htm (EX-99.1) — 28KB
- gri_investorpresentation001.jpg (GRAPHIC) — 87KB
- gri_investorpresentation002.jpg (GRAPHIC) — 204KB
- gri_investorpresentation003.jpg (GRAPHIC) — 165KB
- gri_investorpresentation004.jpg (GRAPHIC) — 116KB
- gri_investorpresentation005.jpg (GRAPHIC) — 131KB
- gri_investorpresentation006.jpg (GRAPHIC) — 128KB
- gri_investorpresentation007.jpg (GRAPHIC) — 157KB
- gri_investorpresentation008.jpg (GRAPHIC) — 83KB
- gri_investorpresentation009.jpg (GRAPHIC) — 129KB
- gri_investorpresentation010.jpg (GRAPHIC) — 102KB
- gri_investorpresentation011.jpg (GRAPHIC) — 142KB
- gri_investorpresentation012.jpg (GRAPHIC) — 106KB
- gri_investorpresentation013.jpg (GRAPHIC) — 114KB
- gri_investorpresentation014.jpg (GRAPHIC) — 132KB
- gri_investorpresentation015.jpg (GRAPHIC) — 156KB
- gri_investorpresentation016.jpg (GRAPHIC) — 145KB
- gri_investorpresentation017.jpg (GRAPHIC) — 146KB
- gri_investorpresentation018.jpg (GRAPHIC) — 99KB
- gri_investorpresentation019.jpg (GRAPHIC) — 153KB
- gri_investorpresentation020.jpg (GRAPHIC) — 98KB
- gri_investorpresentation021.jpg (GRAPHIC) — 126KB
- gri_investorpresentation022.jpg (GRAPHIC) — 116KB
- gri_investorpresentation023.jpg (GRAPHIC) — 87KB
- val-20250820_g1.jpg (GRAPHIC) — 16KB
- val-20250820_g2.jpg (GRAPHIC) — 2KB
- 0001824293-25-000126.txt ( ) — 4237KB
- val-20250820.xsd (EX-101.SCH) — 2KB
- val-20250820_lab.xml (EX-101.LAB) — 23KB
- val-20250820_pre.xml (EX-101.PRE) — 13KB
- val-20250820_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 GRI Bio, Inc. Corporate Presentation, dated August 20, 2025.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 20, 2025 GRI BIO, INC. By: /s/ Leanne Kelly Name: Leanne Kelly Title: Chief Financial Officer